Clinical Trials: Regulatory Submissions (CTD/eCTD)

CTD and eCTD Submissions: Structure and Best Practices

Posted on digi By digi

The Common Technical Document (CTD) and its electronic counterpart, eCTD, are the standardized formats for submitting clinical trial and marketing authorization applications globally. For US sponsors, the FDA mandates electronic submissions in eCTD format for most INDs, NDAs, and BLAs under the Electronic Submissions Gateway (ESG). The structure, completeness, and quality of these submissions directly determine regulatory acceptance and review timelines. Poorly compiled CTDs can result in Refuse-to-File (RTF) decisions or technical rejections.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Breaking Down CTD Modules: FDA and ICH Perspectives

Posted on digi By digi

The Common Technical Document (CTD) is the globally harmonized structure for regulatory submissions, and the electronic CTD (eCTD) has become the mandatory format for US FDA submissions under the Electronic Submissions Gateway (ESG). CTD modules organize regulatory information into five core sections, ensuring consistency, completeness, and efficient review by regulators. For sponsors, correct structuring of modules is critical, as deficiencies often result in technical rejections, Refuse-to-File (RTF) decisions, or inspection findings. The FDA and ICH provide clear expectations on module content, structure, and lifecycle management.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

eCTD Lifecycle Management: Compliance and Operational Challenges

Posted on digi By digi

The electronic Common Technical Document (eCTD) is the mandatory format for US FDA submissions, including INDs, NDAs, and BLAs, through the Electronic Submissions Gateway (ESG). Unlike static submissions, eCTD operates as a sequence-based lifecycle, where new, replaced, or withdrawn documents are tracked to maintain submission history. For US sponsors, FDA technical validation ensures submissions are consistent, traceable, and review-ready. Poor lifecycle management results in technical rejection, delayed reviews, or inspection findings. EMA, ICH, and WHO have also harmonized requirements, making lifecycle oversight critical for global submissions.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Common Issues in CTD/eCTD Submissions and How to Address Them

Posted on digi By digi

The Common Technical Document (CTD) and electronic CTD (eCTD) form the global standard for regulatory submissions to agencies including the FDA, EMA, and Health Canada. For US sponsors, the FDA requires eCTD format for most IND, NDA, and BLA submissions under the Electronic Submissions Gateway (ESG). Despite harmonization under ICH M4 guidelines, many submissions face technical rejections or regulatory queries due to common, avoidable issues. Understanding these pitfalls and implementing preventive measures is crucial for maintaining compliance and avoiding costly delays.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Stability Data in CTD Submissions: Regulatory Expectations

Posted on digi By digi

Stability data is a cornerstone of Module 3 in CTD submissions, providing evidence that an investigational product maintains its intended quality, safety, and efficacy throughout its shelf life. For US sponsors, the FDA requires stability studies to align with 21 CFR Part 211.166 and ICH Q1A–Q1E guidelines. These data support expiry dating, storage conditions, and quality assurance of the drug substance and product. Inadequate or incomplete stability data is one of the most common deficiencies cited by the FDA and EMA in regulatory reviews.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Module 5: Clinical Study Reports in CTD Submissions

Posted on digi By digi

Module 5 of the Common Technical Document (CTD) houses clinical study reports (CSRs), case report forms (CRFs), and datasets, making it one of the most scrutinized sections by regulators. For US sponsors, the FDA requires Module 5 to be comprehensive, accurate, and aligned with 21 CFR Part 312 and ICH E3 Guidance on Structure and Content of Clinical Study Reports. This module directly informs regulatory decisions on safety and efficacy. Incomplete or poorly organized submissions often lead to Refuse-to-File (RTF) decisions or significant review delays.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)